• 1
    Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000; 15: 1293-1301.
  • 2
    Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg. 1996; 33: 817-872.
  • 3
    Katz SC, DeMatteo RP. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol. 2008; 97: 350-359.
  • 4
    Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am. 2009; 23: 115-127, ix.
  • 5
    Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol. 2001; 8: 290-299.
  • 6
    DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001; 234: 540-547; discussion 547-548.
  • 7
    Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg; 2006; 141: 537-543; discussion 543-544.
  • 8
    Nunobe S, Sano T, Shimada K, Sakamoto Y, Kosuge T. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol. 2005; 35: 338-341.
  • 9
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480.
  • 10
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-580.
  • 11
    Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors 1 centimeter or less in size. Am J Pathol. 2002; 160: 1567-1572.
  • 12
    DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007; 245: 347-352.
  • 13
    Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Annals of Surg Oncol. 2007; 14(2): 942953.
  • 14
    Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg. 2003; 186: 665-669.
  • 15
    Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005; 11: 4182-4190.
  • 16
    Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004; 64: 5913-5919.
  • 17
    Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21: 4342-4349.
  • 18
    Zhu J, Yang Y, Zhou L, Jiang M, Hou M. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome [serial online]. BMC Cancer. 2010; 10: 199.
  • 19
    Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-1104.
  • 20
    Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today. 2010; 40: 936-942.
  • 21
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 1.2011. Fort Washington, PA: NCCN; 2011.
  • 22
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery. 2004; 240: 205-213.
  • 23
    Strasberg SM; The International Hepato-Pancreato-Biliary Association Terminology Committee Survey. The Brisbane 2000 Terminology of Liver Anatomy and Resections. HBP (Oxf). 2000; 2: 333-339.
  • 24
    Reddy SK, AS Barbas, RS Turley, et al. A standard definition of major hepatectomy: resection of 4 or more liver segments. HPB (Oxf). 2011; 13: 494-501.
  • 25
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 26
    Cox D. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
  • 27
    Gronnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal. 1996; 2: 315-328.
  • 28
    Haller F, Detken S, Schulten HJ, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007; 14: 526-532.
  • 29
    Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-1134.
  • 30
    Chaudhry UI, DeMatteo RP. Management of resectable gastrointestinal stromal tumor. Hematol Oncol Clin North Am. 2009; 23: 79-96, viii.
  • 31
    Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004; 66: 411-421.